Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c
November 10, 2021 4:40 PM ESTRegulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08).
As of September 30, 2021, Regulus had $35.8 million in cash and cash equivalents.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More